Monograph Details
|
|
Ob/Gyn
> Infertility
|
|
CETROTIDE |
| Manufacturer |
|
EMD Serono, Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
GnRH antagonist. |
| Generic Name |
|
Cetrorelix (as acetate) 0.25mg, 3mg; per vial; pwd for SC inj after reconstitution. |
| Indications |
|
Inhibition of premature LH surges in women undergoing controlled ovarian stimulation for in vitro fertilization. |
| Children |
|
Not applicable. |
| Adults |
|
Give by SC inj into lower abdominal wall during early to mid-follicular phase; see literature. 3mg once on stimulation day 7, or 0.25mg daily beginning on stimulation day 5 or 6 and continuing until day of hCG administration. |
| Contraindications |
|
Pregnancy (Cat.X). Nursing mothers. |
| Precautions |
|
Do complete gynecological and endocrinological exam first. |
| Adverse Reactions |
|
Ovarian hyperstimulation syndrome, nausea, headache, inj site reactions, elevated enzymes (eg, ALT, alkaline phosphatase). |
| How Supplied |
Vials 0.25mg (w. diluent)—1
3mg (w. diluent)—1 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
